000125591 001__ 125591
000125591 005__ 20240228143318.0
000125591 0247_ $$2doi$$a10.1093/neuonc/now122
000125591 0247_ $$2pmid$$apmid:27298312
000125591 0247_ $$2ISSN$$a1522-8517
000125591 0247_ $$2ISSN$$a1523-5866
000125591 0247_ $$2altmetric$$aaltmetric:8704479
000125591 037__ $$aDKFZ-2017-01717
000125591 041__ $$aeng
000125591 082__ $$a610
000125591 1001_ $$aBurth, Sina$$b0
000125591 245__ $$aClinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
000125591 260__ $$aOxford$$bOxford Univ. Press$$c2016
000125591 3367_ $$2DRIVER$$aarticle
000125591 3367_ $$2DataCite$$aOutput Types/Journal article
000125591 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524734913_26071
000125591 3367_ $$2BibTeX$$aARTICLE
000125591 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000125591 3367_ $$00$$2EndNote$$aJournal Article
000125591 520__ $$aThe purpose of this study was to determine the relevance of clinical data, apparent diffusion coefficient (ADC), and relative cerebral blood volume (rCBV) from dynamic susceptibility contrast (DSC) perfusion and the volume transfer constant (k(trans)) from dynamic contrast-enhanced (DCE) perfusion for predicting overall survival (OS) and progression-free survival (PFS) in newly diagnosed treatment-naïve glioblastoma patients.Preoperative MR scans including standardized contrast-enhanced T1 (cT1), T2 - fluid-attenuated inversion recovery (FLAIR), ADC, DSC, and DCE of 125 patients with subsequent histopathologically confirmed glioblastoma were performed on a 3 Tesla MRI scanner. ADC, DSC, and DCE parameters were analyzed in semiautomatically segmented tumor volumes on contrast-enhanced (CE) cT1 and hyperintense signal changes on T2 FLAIR (ED). Univariate and multivariable Cox regression analyses including age, sex, extent of resection (EOR), and KPS were performed to assess the influence of each parameter on OS and PFS.Univariate Cox regression analysis demonstrated a significant association of age, KPS, and EOR with PFS and age, KPS, EOR, lower ADC, and higher rCBV with OS. Multivariable analysis showed independent significance of male sex, KPS, EOR, and increased rCBVCE for PFS, and age, sex, KPS, and EOR for OS.MRI parameters help to predict OS in a univariate Cox regression analysis, and increased rCBVCE is associated with shorter PFS in the multivariable model. In summary, however, our findings suggest that the relevance of MRI parameters is outperformed by clinical parameters in a multivariable analysis, which limits their prognostic value for survival prediction at the time of initial diagnosis.
000125591 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000125591 588__ $$aDataset connected to CrossRef, PubMed,
000125591 7001_ $$0P:(DE-He78)3da06896bf2a50a84d40c33c3b7a9b3e$$aKickingereder, Philipp$$b1
000125591 7001_ $$aEidel, Oliver$$b2
000125591 7001_ $$0P:(DE-He78)2ef631585610340ff425c9c31fcabd03$$aTichy, Diana$$b3$$udkfz
000125591 7001_ $$0P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93$$aBonekamp, David$$b4
000125591 7001_ $$0P:(DE-He78)002b96e11002301e931d591d8fa8c7d5$$aWeberling, Lukas$$b5
000125591 7001_ $$aWick, Antje$$b6
000125591 7001_ $$aLöw, Sarah$$b7
000125591 7001_ $$0P:(DE-He78)82e0de3d5aa5330bb2470e74c48773ca$$aHertenstein, Anne$$b8
000125591 7001_ $$aNowosielski, Martha$$b9
000125591 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b10
000125591 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b11
000125591 7001_ $$aBendszus, Martin$$b12
000125591 7001_ $$0P:(DE-He78)77588f5b9413339755a66e739d316c7d$$aRadbruch, Alexander$$b13$$eLast author
000125591 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/now122$$gVol. 18, no. 12, p. 1673 - 1679$$n12$$p1673 - 1679$$tNeuro-Oncology$$v18$$x1523-5866$$y2016
000125591 909CO $$ooai:inrepo02.dkfz.de:125591$$pVDB
000125591 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3da06896bf2a50a84d40c33c3b7a9b3e$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000125591 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2ef631585610340ff425c9c31fcabd03$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000125591 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000125591 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)002b96e11002301e931d591d8fa8c7d5$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000125591 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)82e0de3d5aa5330bb2470e74c48773ca$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000125591 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000125591 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000125591 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)77588f5b9413339755a66e739d316c7d$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000125591 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000125591 9141_ $$y2016
000125591 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000125591 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000125591 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2015
000125591 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000125591 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000125591 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000125591 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000125591 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000125591 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000125591 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000125591 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEURO-ONCOLOGY : 2015
000125591 9201_ $$0I:(DE-He78)E012-20160331$$kE012$$lNeuroonkologische Bildgebung$$x0
000125591 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000125591 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x2
000125591 9201_ $$0I:(DE-He78)G160-20160331$$kG160$$lNeuroimmunologie und Hirntumorimmunologie$$x3
000125591 9201_ $$0I:(DE-He78)G370-20160331$$kG370$$lKKE Neuroonkologie$$x4
000125591 980__ $$ajournal
000125591 980__ $$aVDB
000125591 980__ $$aI:(DE-He78)E012-20160331
000125591 980__ $$aI:(DE-He78)C060-20160331
000125591 980__ $$aI:(DE-He78)E010-20160331
000125591 980__ $$aI:(DE-He78)G160-20160331
000125591 980__ $$aI:(DE-He78)G370-20160331
000125591 980__ $$aUNRESTRICTED